A Prospective, Randomized, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of PBK_M2502

NCT07114406 Phase 3 NOT_YET_RECRUITING

This clinical trial was prospective, randomized, single-blind, 3-treatment arm, parallel treatment group, and active-controlled. , Multi-center, Phase 3 confirmatory clinical trial.

Details

Lead sponsor	Pharmbio Korea Co., Ltd.
Phase	Phase 3
Status	NOT_YET_RECRUITING
Enrolment	110
Start date	2025-08
Completion	2026-11

Conditions

• Intestinal Disease
• Colonic Diseases
• Gastrointestinal Disease
• Digestive System Disease

Interventions

• PBK_M2502 1-Day
• PBK_M2502 2-Day

Primary outcomes

• Successful cleansing rate — Day 1 (day of colonoscopy)
  %Patient with HCS-graded A or B

Countries

South Korea